199 related articles for article (PubMed ID: 32629460)
1. A statistical model to identify determinants of glycemic control in patients with type 2 diabetes with different pharmacotherapeutic profiles.
Moura AM; Antunes M; Martins SO; Raposo JF
PLoS One; 2020; 15(7):e0235376. PubMed ID: 32629460
[TBL] [Abstract][Full Text] [Related]
2. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
Koye DN; Montvida O; Paul SK
Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
[TBL] [Abstract][Full Text] [Related]
3. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
Mamza J; Mehta R; Donnelly R; Idris I
Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Yurgin N; Secnik K; Lage MJ
Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
[TBL] [Abstract][Full Text] [Related]
6. Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03).
Yamamoto-Honda R; Takahashi Y; Mori Y; Yamashita S; Yoshida Y; Kawazu S; Iwamoto Y; Kajio H; Yanai H; Mishima S; Handa N; Shimokawa K; Yoshida A; Watanabe H; Ohe K; Shimbo T; Noda M
Intern Med; 2018 May; 57(9):1229-1240. PubMed ID: 29279487
[TBL] [Abstract][Full Text] [Related]
7. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
8. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Fan Y; Zhang Y; Li X; Zheng H; Song Y; Zhang N; Shen C; Fan X; Ren F; Shen J; Ren G; Yang J
Drug Des Devel Ther; 2015; 9():4679-83. PubMed ID: 26316706
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
10. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
12. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
13. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Chow CC; Tsang LW; Sorensen JP; Cockram CS
Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
[TBL] [Abstract][Full Text] [Related]
15. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
16. ANALYSIS OF ANTIDIABETIC THERAPY FOR TYPE 2 DIABETES IN PRIMARY HEALTH CARE (WESTERN KAZAKHSTAN).
Bazargaliyev Y; Tleumagamabetova B; Kudabayeva K; Kosmuratova R
Georgian Med News; 2024 Mar; (348):22-27. PubMed ID: 38807384
[TBL] [Abstract][Full Text] [Related]
17. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
[TBL] [Abstract][Full Text] [Related]
18. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
19. HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes.
Zeitler P; Hirst K; Copeland KC; El Ghormli L; Levitt Katz L; Levitsky LL; Linder B; McGuigan P; White NH; Wilfley D;
Diabetes Care; 2015 Dec; 38(12):2285-92. PubMed ID: 26537182
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
